The diagnostic value of miRNA-141 in prostate cancer: A systematic review and PRISMA-compliant meta-analysis

13Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background:miR-141 has gradually demonstrated its value in the diagnosis of prostate cancer. However, the diagnostic parameters in previous studies differ. A systematic review was conducted to explore the diagnostic value of miR-141 in prostate cancer.Methods:A comprehensive search of the literature in the PubMed, Medline, Cochrane Library, and Embase databases was performed. The included 7 studies assessed the diagnostic value of miR-141 in patients with prostate cancer up to October 31, 2019. We used meta-disc version 1.4 and STATA software version 12.0 to analyze the data.Results:The pooled sensitivity and specificity were 0.70 (95% confidence interval [CI] 0.64-0.75) and 0.73 (95% CI 0.64-0.80), respectively. The positive likelihood ratio was 2.88 (95% CI 1.40-5.93), and the negative likelihood ratio was 0.38 (95% CI 0.20-0.71). Further, we note that the pooled diagnostic odds ratio of miR-141 for prostate cancer was 9.94 (95% CI: 2.55-38.80). The summary area under the receiver operating characteristic curve was 0.83 (95% CI: 0.79-0.86). The results of meta-regression suggested that heterogeneity was mainly derived from patient age. The results of the Fagan nomogram showed that it was increased significantly by testing miR-141 for diagnosing prostate cancer.Conclusion:This meta-analysis suggests that miR-141 has a high diagnostic value for prostate cancer. In the future, large-scale prospective studies are needed to verify and evaluate this result.

Author supplied keywords

References Powered by Scopus

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

53265Citations
N/AReaders
Get full text

Meta-analysis in clinical trials

32778Citations
N/AReaders
Get full text

Cancer statistics, 2019

17476Citations
N/AReaders
Get full text

Cited by Powered by Scopus

CASC11 promotes aggressiveness of prostate cancer cells through miR-145/IGF1R axis

21Citations
N/AReaders
Get full text

Identification of mirnas as viable aggressiveness biomarkers for prostate cancer

15Citations
N/AReaders
Get full text

Smartphone-Interfaced Electrochemical Biosensor for microRNA Detection Based on Laser-Induced Graphene with π-π Stacked Peptide Nucleic Acid Probes

15Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ye, Y., Yuan, X. H., Wang, J. J., Wang, Y. C., Li, S. L., & Ding, J. (2020, May 29). The diagnostic value of miRNA-141 in prostate cancer: A systematic review and PRISMA-compliant meta-analysis. Medicine (United States). Lippincott Williams and Wilkins. https://doi.org/10.1097/MD.0000000000019993

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 9

75%

Professor / Associate Prof. 1

8%

Lecturer / Post doc 1

8%

Researcher 1

8%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

33%

Biochemistry, Genetics and Molecular Bi... 3

33%

Immunology and Microbiology 2

22%

Pharmacology, Toxicology and Pharmaceut... 1

11%

Save time finding and organizing research with Mendeley

Sign up for free